abrdn Life Sciences Investors Shares of Beneficial Interest (HQL)
SG&A Expenses
$9.95M
TTM · Period ending: · USD
HQL SG&A Expenses
Latest reported$9.95Mperiod ending
Latest reported$9.95Mperiod ending
HQL TTM SG&A Expenses ($190.00K → $9.95M)
TTM SG&A Expenses
High-resolution chart · PNG
HQL sg&a expenses history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | SG&A Expenses (USD) |
|---|---|
| 9,949,328 | |
| 9,380,611 | |
| 6,670,559 | |
| 6,803,471 | |
| 5,064,702 | |
| 2,347,664 | |
| 4,316,193 | |
| 1,447,738 | |
| 6,206 | |
| 5,966 | |
| 2,635,488 | |
| 5,322,377 | |
| 8,136,348 | |
| 10,912,558 | |
| 8,284,378 | |
| 5,598,495 | |
| 2,785,572 | |
| 10,789 | |
| 10,973 | |
| 11,273 | |
| 11,196 | |
| 10,687 | |
| 9,432 | |
| 7,445 | |
| 1,855,781 | |
| 3,430,721 | |
| 4,003,802 | |
| 4,577,918 | |
| 3,042,180 | |
| 1,780,000 | |
| 1,500,000 | |
| 1,220,000 | |
| 1,245,000 | |
| 1,270,000 | |
| 1,335,000 | |
| 1,400,000 | |
| 1,335,000 | |
| 1,270,000 | |
| 1,165,000 | |
| 1,060,000 | |
| 1,050,000 | |
| 1,040,000 | |
| 1,010,000 | |
| 980,000 | |
| 950,000 | |
| 920,000 | |
| 865,000 | |
| 810,000 | |
| 690,000 | |
| 570,000 | |
| 495,000 | |
| 420,000 | |
| 305,000 | |
| 190,000 |